Iain L. Lamont

University of Otago — New Zealand

Biochemistry, Genetics and Molecular Biology · Life Sciences

49h-index8.1kcitations145works5.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bacterial biofilms and quorum sensing(65), Bacterial Genetics and Biotechnology(51), Antibiotic Resistance in Bacteria(49), Cystic Fibrosis Research Advances(31), Plant Pathogenic Bacteria Studies(16)

Publications145 total

Dietary Iron Intake Impacts the Microbial Composition of the Murine Intestinal and Lung Microbiome
Nutrients·2025· 2 citedOpen Access
Azithromycin represses evolution of ceftazidime/avibactam resistance by translational repression of <i>rpoS</i> in <i>Pseudomonas aeruginosa</i>
Journal of Bacteriology·2025Open Access
A sensitive reverse-phase ultra performance liquid chromatography-tandem mass spectrometry method for the determination of tobramycin in Pseudomonas aeruginosa cell lysate
Journal of Pharmaceutical and Biomedical Analysis·2025· 1 cited
Anaerobiosis and Mutations Can Reduce Susceptibility of Pseudomonas aeruginosa to Tobramycin Without Reducing the Cellular Concentration of the Antibiotic
Pathogens·2025Open Access
A Sensitive Ultra Performance Reverse Phase Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Tobramycin in Pseudomonas Aeruginosa Cell Lysate
SSRN Electronic Journal·2025· 1 citedOpen Access
Uncertainty quantification for severe-accident reactor modelling: Results and conclusions of the MUSA reactor applications work package
Annals of Nuclear Energy·2024· 15 citedOpen Access
Characterization of acquired β-lactamases in <i>Pseudomonas aeruginosa</i> and quantification of their contributions to resistance
Microbiology Spectrum·2024· 5 citedOpen Access
Penicillin-binding protein 3 sequence variations reduce susceptibility of <i>Pseudomonas aeruginosa</i> to β-lactams but inhibit cell division
Journal of Antimicrobial Chemotherapy·2024· 17 citedOpen Access
Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective against Pseudomonas aeruginosa
Frontiers in Cellular and Infection Microbiology·2024· 8 citedOpen Access
Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against <i>Pseudomonas aeruginosa</i> by enhancing membrane potential
Antimicrobial Agents and Chemotherapy·2024· 8 citedOpen Access
The PitA protein contributes to colistin susceptibility in Pseudomonas aeruginosa
PLoS ONE·2023· 3 citedOpen Access
Murepavadin induces envelope stress response and enhances the killing efficacies of β-lactam antibiotics by impairing the outer membrane integrity of <i>Pseudomonas aeruginosa</i>
Microbiology Spectrum·2023· 12 citedOpen Access
Glutamate racemase is a compelling target for antibiotic design for the treatment of infections caused by <i>Pseudomonas aeruginosa</i>
Acta Crystallographica Section A Foundations and Advances·2023Open Access
Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex
PLoS ONE·2023· 18 citedOpen Access
Gene–Gene Interactions Reduce Aminoglycoside Susceptibility of Pseudomonas aeruginosa through Efflux Pump-Dependent and -Independent Mechanisms
Antibiotics·2023· 16 citedOpen Access
<i>Pseudomonas aeruginosa</i> is oxygen-deprived during infection in cystic fibrosis lungs, reducing the effectiveness of antibiotics
FEMS Microbiology Letters·2023· 16 citedOpen Access
Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation
European Journal of Pharmaceutics and Biopharmaceutics·2022· 7 cited
One Health Aotearoa: a transdisciplinary initiative to improve human, animal and environmental health in New Zealand
New Zealand Science Review·2022Open Access
Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics
Antibiotics·2022· 43 citedOpen Access
Aminoglycoside resistance in Pseudomonas aeruginosa: the contribution of the MexXY-OprM efflux pump varies between isolates
Journal of Medical Microbiology·2022· 20 cited
page 1 of 8Next →

Frequent Co-authors

Lois W. Martin(9), David W. Reid(5), Megan J. Wilson(4), Brendan J. McMorran(4), Paul A. Beare(3), Michael L. Vasil(3), Paolo Visca(3), Paul Williams(3), Andrea Donaldson(3), Heather E. Cunliffe(3), Tony R. Merriman(3), Emilie Yeterian(3), Isabelle J. Schalk(3), Phil Bremer(3), A. James McQuillan(3), Urs A. Ochsner(2), Adriana I. Vasil(2), Francesco Imperi(2), Miguel Cámara(2), Zaiga Johnson(2)